Investor Relations

Unique investment opportunity for industry and financial partners

Investor Relations

Novaliq is a private ophthalmic pharmaceutical company based in Heidelberg, Germany with a subsidiary in Cambridge, U.S.

With its fast and proven drug development process and its rich pipeline of differentiated products, Novaliq provides a unique investment opportunity for industry and financial partners.

About us

The company is dedicated to the development of innovative pharmaceuticals based on their water-free EyeSol^® technology platform. We actively invite Partners and Investors to join our success story to bring Novaliq to the next level.

Novaliq has successfully acquired a total capital sum of $115 million. The principal shareholder of the company is the dievini Hopp BioTech Holding GmbH & Co. KG.

Do you want further information on investment opportunities?